Rethinking cancer vaccines to improve efficacy
Nature Medicine
2013년3월4일
The limited success that cancer vaccine therapies have in eliminating tumors in patients may be due to their formulation. These findings in a mouse model of melanoma, published this week in Nature Medicine, could have implications for vaccine therapy development in general.
Willem Overwijk and colleagues show that peptide antigens formulated in a water in oil emulsion to induce melanoma-specific immune responses sequester T cells at the site of injection in mice-instead of inducing their recruitment to the tumor site-leading to T cell dysfunction and eventually apoptosis. A peptide and adjuvant formulation that did not persist at the injection site for long periods of time showed superior ability to induce a functional antitumor T cell response. The results suggest that whereas some vaccine adjuvants impair the efficacy of vaccines, formulations that are more rapidly degraded may improve clinical results by preventing retention of T cells at the injection site and redirecting T cells to sites of disease.
doi: 10.1038/nm.3105
리서치 하이라이트
-
6월24일
Sport science: New wearable sensor to measure neck strain may detect potential concussionScientific Reports
-
6월23일
Scientific community: Women credited less than men in scientific paper authorshipNature
-
6월17일
Health technology: New cost-effective smartphone test for middle ear functionCommunications Medicine
-
6월16일
An exercise-inducible molecule that suppresses appetiteNature
-
6월16일
Cancer: Signatures of structural genomic variation in cancerNature
-
6월10일
Animals: Genetic clues to how dogs became man’s best friendsScientific Reports